Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia

Multidrug resistance (MDR) development has emerged as a complication that compromises the success of several chemotherapeutic agents. In chronic myeloid leukemia (CML), imatinib resistance has been associated with changes in BCR-ABL1 and intracellular drug concentration, controlled by SLC and ABC tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Alves, Raquel, Gonçalves, Ana Cristina, Jorge, Joana, Almeida, António M., Sarmento-Ribeiro, Ana Bela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138473/
https://www.ncbi.nlm.nih.gov/pubmed/35625893
http://dx.doi.org/10.3390/biomedicines10051158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138473/
https://www.ncbi.nlm.nih.gov/pubmed/35625893
http://dx.doi.org/10.3390/biomedicines10051158

Ejemplares similares